GlassScriptPhysician profile
Andree B Caillet
NPI 1700888005
$4,036.86
in general payments reported to CMS, 2019-2025
34 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $414 · 2021: $677 · 2022: $650 · 2023: $916 · 2024: $679 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $740.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $522.58 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $397.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $367.35 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.63 | 2019-2024 | Ofev, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $264.13 | 2020-2025 | Trintellix |
| Amgen INC. | $155.54 | 2020-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $135.46 | 2020-2024 | |
| Exact Sciences Corporation | $132.28 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $126.47 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $107.04 | 2020-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $99.40 | 2019-2022 | |
| Noven Therapeutics, LLC | $98.02 | 2023-2025 | Xelstrym |
| Novartis Pharmaceuticals Corporation | $69.96 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $59.48 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $43.97 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $35.10 | 2021-2025 | Zoryve |
| Eisai INC. | $33.16 | 2021 | |
| Merck Sharp & Dohme LLC | $33.09 | 2020-2025 | Capvaxive, Gardasil 9 |
| Horizon Therapeutics Plc | $28.73 | 2023 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $27.09 | 2024-2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $23.84 | 2021 | |
| Bausch Health US, LLC | $23.32 | 2022 | |
| Glaxosmithkline, LLC. | $19.08 | 2023 | Trelegy Ellipta |
| Biogen, INC. | $17.65 | 2024 | Skyclarys |
| Sanofi Pasteur INC. | $17.20 | 2023 | |
| Silk Road Medical, INC. | $15.56 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Idorsia Pharmaceuticals US INC | $14.28 | 2023 | Quviviq |
| Genentech USA, INC. | $14.23 | 2020 | |
| Amarin Pharma, INC. | $13.90 | 2022 | |
| Neos Therapeutics, LP | $13.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2020 | |
| Currax Pharmaceuticals LLC | $12.03 | 2019 | |
| Allergan, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andree Caillet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.